Pediatric Study Plans for Oncology Drugs: Transitional Information Until Full Implementation of FDARA Section 504 Questions and Answers

On 15 January 2020 FDA announced the availability of the guide for industry. Comments may submit by 16 March 2020.

The purpose of this guidance is to provide information to sponsors regarding the submission of an initial pediatric study plan (iPSP), as required by section 505B(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for oncology drugs only. Specifically, this guidance provides FDA’s current thinking regarding iPSPs for oncology drugs in light of the amendments to section 505B of the FD&C Act (also referred to as the Pediatric Research Equity Act, or PREA) made by section 504 of the FDA Reauthorization Act of 2017 (FDARA). FDA has received a number of questions on this topic and, as a result, is providing guidance in a question and answer format, addressing the most frequently asked questions.

This guidance does not contain a complete discussion of general requirements for development 28 of drugs for pediatric use under PREA or section 505A of the FD&C Act (also referred to as the 29 Best Pharmaceuticals for Children Act or BPCA).

Read more online
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /